Compare IRIX & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | TRIB |
|---|---|---|
| Founded | 1989 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 18.3M |
| IPO Year | 1996 | N/A |
| Metric | IRIX | TRIB |
|---|---|---|
| Price | $0.94 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 106.9K | 55.3K |
| Earning Date | 11-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,647,000.00 | ★ $61,555,000.00 |
| Revenue This Year | $9.61 | $13.51 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.58 | ★ 8.31 |
| 52 Week Low | $0.78 | $0.48 |
| 52 Week High | $1.90 | $3.44 |
| Indicator | IRIX | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 50.30 |
| Support Level | $0.91 | $0.95 |
| Resistance Level | $0.97 | $0.94 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 44.72 | 64.29 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.